Stay updated on Trametinib and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.
Latest updates to the Trametinib and Pembrolizumab in NSCLC Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedLocations section now lists Connecticut and Texas as study sites, with the revision updated to v3.3.3. The HHS Vulnerability Disclosure link appears removed.SummaryDifference0.3%
- Check55 days agoChange DetectedA new revision label v3.3.2 is shown, and the previous v3.2.0 label is removed.SummaryDifference0.1%
- Check62 days agoChange DetectedRemoved the government funding lapse notice that warned users about potential outdated information and possible processing delays, along with the NIH/OPM operating status links. This does not alter the study details, eligibility criteria, or other substantive content on the page.SummaryDifference0.4%
- Check76 days agoChange DetectedNo significant additions or deletions were detected; the content appears unchanged between the two screenshots. Any minor differences are likely routine timestamp updates that do not affect the page's purpose.SummaryDifference0.4%
- Check105 days agoChange DetectedMajor changes include a user-visible status notice about government funding and NIH Clinical Center operations, and a version update from v3.1.0 to v3.2.0.SummaryDifference2%
Stay in the know with updates to Trametinib and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.